BDBM808962 US12637469, Compound 1
SMILES c1cn2c(n1)c(Nc1ccc(N3CCOCC3)cc1)nc1ccc(-c3cn[nH]c3)cc12
InChI Key InChIKey=XOQYFYRFHLPTRU-UHFFFAOYSA-N
Data 72 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 72 hits for monomerid = 808962
TargetReceptor-type tyrosine-protein kinase FLT3(Human)
Ocumension Therapeutics (Suzhou) Co.
US Patent
Ocumension Therapeutics (Suzhou) Co.
US Patent
Affinity DataIC50: 12nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 15nMAssay Description:Table 1: Experimental steps and methods:a) Compound dilution and plate making1) The compound powder is weighed, dissolved in a certain amount of DMSO...More data for this Ligand-Target Pair
Ligand Info
TargetVascular endothelial growth factor receptor 2(Human)
Ocumension Therapeutics (Suzhou) Co.
US Patent
Ocumension Therapeutics (Suzhou) Co.
US Patent
Affinity DataIC50: 23nMAssay Description:In Vitro Test of the Compound's Inhibitory Effect on VEGFR2 Kinase Experimental Methods and Procedures: The ADP-GLO Kinase Assay is an analytical rea...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 50nMAssay Description:Table 3: Experimental methods and procedures1) Prepare test compound and standard inhibitor working solution (100×);2) Take the microsomes out of the...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 50nMAssay Description:Table 3: Experimental methods and procedures1) Prepare test compound and standard inhibitor working solution (100×);2) Take the microsomes out of the...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 50nMAssay Description:Table 3: Experimental methods and procedures1) Prepare test compound and standard inhibitor working solution (100×);2) Take the microsomes out of the...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 50nMAssay Description:Table 3: Experimental methods and procedures1) Prepare test compound and standard inhibitor working solution (100×);2) Take the microsomes out of the...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 50nMAssay Description:Table 3: Experimental methods and procedures1) Prepare test compound and standard inhibitor working solution (100×);2) Take the microsomes out of the...More data for this Ligand-Target Pair
Ligand Info
TargetMitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4)(Human)
Ocumension Therapeutics (Suzhou) Co.
US Patent
Ocumension Therapeutics (Suzhou) Co.
US Patent
Affinity DataIC50: 63nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 91nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
TargetVascular endothelial growth factor receptor 1 (Human)
Ocumension Therapeutics (Suzhou) Co.
US Patent
Ocumension Therapeutics (Suzhou) Co.
US Patent
Affinity DataIC50: 104nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
TargetHigh affinity nerve growth factor receptor (TrkA)(Human)
Ocumension Therapeutics (Suzhou) Co.
US Patent
Ocumension Therapeutics (Suzhou) Co.
US Patent
Affinity DataIC50: 112nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 117nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 141nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 152nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 204nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 227nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 232nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 279nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
TargetProto-oncogene tyrosine-protein kinase Src(Human)
Ocumension Therapeutics (Suzhou) Co.
US Patent
Ocumension Therapeutics (Suzhou) Co.
US Patent
Affinity DataIC50: 367nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 373nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 385nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 418nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 469nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 499nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 550nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 663nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Human)
Ocumension Therapeutics (Suzhou) Co.
US Patent
Ocumension Therapeutics (Suzhou) Co.
US Patent
Affinity DataIC50: 756nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 775nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
TargetProto-oncogene tyrosine-protein kinase Src [1-530](Human)
Ocumension Therapeutics (Suzhou) Co.
US Patent
Ocumension Therapeutics (Suzhou) Co.
US Patent
Affinity DataIC50: 827nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 847nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 934nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
TargetInhibitor of nuclear factor kappa-B kinase subunit alpha(Human)
Ocumension Therapeutics (Suzhou) Co.
US Patent
Ocumension Therapeutics (Suzhou) Co.
US Patent
Affinity DataIC50: 946nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
TargetProto-oncogene tyrosine-protein kinase Src [T341M](Human)
Ocumension Therapeutics (Suzhou) Co.
US Patent
Ocumension Therapeutics (Suzhou) Co.
US Patent
Affinity DataIC50: 1.01E+3nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 1.04E+3nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 1.17E+3nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 1.31E+3nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 1.85E+3nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 2.06E+3nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
TargetPlatelet-derived growth factor receptor alpha(Human)
Ocumension Therapeutics (Suzhou) Co.
US Patent
Ocumension Therapeutics (Suzhou) Co.
US Patent
Affinity DataIC50: 2.70E+3nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 2.84E+3nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
TargetMitogen-activated protein kinase 13 (SAPK4)(Human)
Ocumension Therapeutics (Suzhou) Co.
US Patent
Ocumension Therapeutics (Suzhou) Co.
US Patent
Affinity DataIC50: 1.00E+4nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 1.00E+4nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 1.00E+4nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
TargetTyrosine-protein kinase receptor TYRO3 (RSE)(Human)
Ocumension Therapeutics (Suzhou) Co.
US Patent
Ocumension Therapeutics (Suzhou) Co.
US Patent
Affinity DataIC50: 1.00E+4nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
TargetMitogen-activated protein kinase 14 (SAPK2a)(Human)
Ocumension Therapeutics (Suzhou) Co.
US Patent
Ocumension Therapeutics (Suzhou) Co.
US Patent
Affinity DataIC50: 1.00E+4nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 1.00E+4nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
TargetMitogen-activated protein kinase 11 (SAPK2b)(Human)
Ocumension Therapeutics (Suzhou) Co.
US Patent
Ocumension Therapeutics (Suzhou) Co.
US Patent
Affinity DataIC50: 1.00E+4nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
Affinity DataIC50: 1.00E+4nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
TargetMitogen-activated protein kinase 12 (SAPK3)(Human)
Ocumension Therapeutics (Suzhou) Co.
US Patent
Ocumension Therapeutics (Suzhou) Co.
US Patent
Affinity DataIC50: 1.00E+4nMAssay Description:Table 2: Purpose: In order to investigate the specificity of compounds for target inhibition, this study tested the activity and selectivity of test ...More data for this Ligand-Target Pair
Ligand Info
